Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 135Lymphoid 17Other hematologic neoplasm 15Thoracic 2Myeloid 2Genitourinary 2CNS 2Tumor-Agnostic 1Other solid neoplasm 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 347pembrolizumab 322Pemetrexed 246Cisplatin 218Paclitaxel 147Nivolumab 138durvalumab 133osimertinib 112Docetaxel 111atezolizumab 109Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 76Radiosurgery 72Gemcitabine 71Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 44Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
daratumumab × Thoracic × 1 year × Clear all
NCT06015724 2026-05-15

DARANIVOVAX

Georgetown University

Phase 2 Recruiting
54 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05807048 2026-03-10

Daratumumab in STK11 Mutated NSCLC

NYU Langone Health

Phase 2 Completed
8 enrolled
Thoracic

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡